Physician

Elvin R. Garcia, M.D.

According to 2025 Medicare claims, Elvin Garcia, M.D. (NPI: 1871547596) practices rheumatology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is ELVIN R. GARCIA, MD., PA. (NPI: 1801907894; TIN: 710905290) and primary practice location at 78501-1401. Garcia is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Garcia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 694 traditional Medicare patients, billed 109,428 HCPCS/CPT codes, and received $1,414,467 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 42,032 prescription claims across 3,573 beneficiaries totaling $43,351,968 in drug costs, led by Krystexxa (Pegloticase). 2018 DME data shows 19 claims. Open Payments data shows 37 records totaling $172,752. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $11,010,622 to $43,351,968. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $658 to $1,642.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,613	97,746	$1,650,788
2016	1,453	102,747	$1,791,221
2017	1,692	120,540	$2,409,970
2018	1,672	141,704	$2,471,137
2019	1,731	137,890	$2,324,860
2020	1,460	124,189	$2,294,131
2021	1,165	138,602	$2,139,266
2022	982	114,077	$1,826,788
2023	856	118,832	$1,733,823
2024	694	109,428	$1,414,467

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	2,383	23,854	$11,010,622
2016	2,478	24,336	$13,880,781
2017	2,566	20,610	$15,267,513
2018	2,746	19,317	$18,066,045
2019	2,910	20,839	$20,786,969
2020	3,207	28,921	$24,538,323
2021	3,287	35,561	$28,667,825
2022	3,354	38,787	$33,183,582
2023	3,515	41,770	$43,528,300
2024	3,573	42,032	$43,351,968

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$124
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	19	$299
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	495	1,111	$86
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	330	475	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	353	539	$5
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	368	555	$4
J1100	Injection, dexamethasone sodium phosphate, 1 mg	341	29,516	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Krystexxa	Pegloticase	230	6,440	$13,732,442
Humira(Cf) Pen	Adalimumab	394	12,268	$3,622,772
Enbrel Sureclick	Etanercept	433	12,718	$3,362,631
Orencia	Abatacept/Maltose	518	14,427	$2,269,585
Rituxan	Rituximab	115	11,154	$1,965,582

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$12,825	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$159,927	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Elvin R. Garcia, M.D.?

Tedicare shows public-source Medicare data for Elvin R. Garcia, M.D. (NPI 1871547596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Elvin R. Garcia, M.D. have ACO affiliation data?

Elvin R. Garcia, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Elvin R. Garcia, M.D.?

Elvin R. Garcia, M.D. is linked to ELVIN R. GARCIA, MD., PA. (billing NPI 1801907894) in the available physician profile data.

Does Elvin R. Garcia, M.D. have Open Payments data?

Elvin R. Garcia, M.D. has 37 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.